BR112018074056A2 - composições e métodos relacionados a construtos de fc manipulados - Google Patents

composições e métodos relacionados a construtos de fc manipulados

Info

Publication number
BR112018074056A2
BR112018074056A2 BR112018074056-0A BR112018074056A BR112018074056A2 BR 112018074056 A2 BR112018074056 A2 BR 112018074056A2 BR 112018074056 A BR112018074056 A BR 112018074056A BR 112018074056 A2 BR112018074056 A2 BR 112018074056A2
Authority
BR
Brazil
Prior art keywords
constructs
manipulated
compositions
methods related
methods
Prior art date
Application number
BR112018074056-0A
Other languages
English (en)
Inventor
J. Bosques Carlos
C. Lansing Jonathan
Ortiz Daniel
Rutitzky Laura
J. Washburn Nathaniel
Original Assignee
Momenta Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals, Inc. filed Critical Momenta Pharmaceuticals, Inc.
Publication of BR112018074056A2 publication Critical patent/BR112018074056A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Prostheses (AREA)

Abstract

a presente invenção refere-se a construtos de fc de igg manipulados e seus usos.
BR112018074056-0A 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados BR112018074056A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662340322P 2016-05-23 2016-05-23
US62/340,322 2016-05-23
US201762443451P 2017-01-06 2017-01-06
US62/443,451 2017-01-06
PCT/US2017/034084 WO2017205434A1 (en) 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs

Publications (1)

Publication Number Publication Date
BR112018074056A2 true BR112018074056A2 (pt) 2019-03-06

Family

ID=60412547

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018074032-2A BR112018074032A2 (pt) 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados
BR112018074056-0A BR112018074056A2 (pt) 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112018074032-2A BR112018074032A2 (pt) 2016-05-23 2017-05-23 composições e métodos relacionados a construtos de fc manipulados

Country Status (14)

Country Link
US (4) US11155640B2 (pt)
EP (2) EP3484514B1 (pt)
JP (4) JP2019519527A (pt)
KR (3) KR102635635B1 (pt)
CN (4) CN109963869A (pt)
AU (2) AU2017272109B2 (pt)
BR (2) BR112018074032A2 (pt)
CA (2) CA3025310A1 (pt)
DK (1) DK3484514T3 (pt)
ES (1) ES2973251T3 (pt)
IL (3) IL309293A (pt)
PL (1) PL3484514T3 (pt)
SG (3) SG10202011624SA (pt)
WO (2) WO2017205436A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015168643A2 (en) 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
CN109963869A (zh) 2016-05-23 2019-07-02 动量制药公司 与经改造的Fc构建体相关的组合物和方法
JP7146771B2 (ja) 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法
CA3106142A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
MX2021000281A (es) * 2018-07-11 2021-11-12 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1.
MX2021000305A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
CN113164590A (zh) * 2018-07-11 2021-07-23 动量制药公司 与靶向CCR4的工程化Fc-抗原结合结构域构建体有关的组合物和方法
CN113164592A (zh) * 2018-07-11 2021-07-23 动量制药公司 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
US20210317227A1 (en) * 2018-07-11 2021-10-14 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
CA3106212A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
MX2021000306A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4.
KR102661494B1 (ko) 2019-03-08 2024-04-29 에이치엘만도 주식회사 랙구동형 동력 보조 조향장치
BR112022003713A2 (pt) 2019-09-13 2022-08-09 CSL Behring Lengnau AG Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo
WO2021111007A1 (en) 2019-12-06 2021-06-10 CSL Behring Lengnau AG Stable compositions of fc multimers
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
CA3201120A1 (en) * 2020-12-07 2022-06-16 William Brondyk Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
US5426641A (en) 1994-01-28 1995-06-20 Bell Communications Research, Inc. Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0975355A2 (en) 1996-06-14 2000-02-02 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US20090074839A1 (en) 1997-01-22 2009-03-19 Marton Milankovits Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2390691C (en) 1999-12-24 2016-05-10 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
AU2007343796A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
BRPI0620639A2 (pt) 2006-12-21 2011-11-22 Micromet Ag anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
HUE028536T2 (en) * 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
AU2009231991B2 (en) 2008-04-02 2014-09-25 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
CA2739581A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US20100143353A1 (en) 2008-12-04 2010-06-10 Mosser David M POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (lgG) AND METHODS OF USING THE SAME
US10865233B2 (en) 2008-12-18 2020-12-15 Dana-Farber Cancer Institute, Inc. NKG2D-fc for immunotherapy
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
US20120064008A1 (en) 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
AU2010249787A1 (en) 2009-05-20 2011-12-22 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2011008517A2 (en) 2009-06-30 2011-01-20 Research Development Foundation Immunoglobulin fc polypeptides
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011063348A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Monomeric antibody fc
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
CA2800173C (en) * 2010-05-21 2019-05-14 Ulrik Nielsen Bi-specific fusion proteins
NZ605400A (en) 2010-07-09 2015-05-29 Biogen Idec Hemophilia Inc Chimeric clotting factors
PL2598533T3 (pl) 2010-07-28 2019-07-31 Gliknik Inc. Białka fuzyjne naturalnych fragmentów białka ludzkiego do tworzenia uporządkowanych multimeryzowanych kompozycji Fc immunoglobulin
EP2603526A1 (en) 2010-08-13 2013-06-19 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
CA2822366A1 (en) * 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
US9624291B2 (en) 2011-03-17 2017-04-18 Ramot At Tel-Aviv University Ltd. Bi- and monospecific, asymmetric antibodies and methods of generating the same
CA2812739A1 (en) 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
AU2013270682A1 (en) * 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
CN104582736A (zh) * 2012-06-21 2015-04-29 印第安纳大学研究及科技有限公司 Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物
KR20150058236A (ko) * 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
AU2012392760C1 (en) 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins
CN104558194B (zh) * 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
CN106029087A (zh) * 2013-12-20 2016-10-12 印第安纳大学研究及科技有限公司 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽
EP3094649A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding properties
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
EP3114143B1 (en) 2014-03-05 2020-07-08 UCB Biopharma SRL Multimeric fc proteins
SG11201606596PA (en) 2014-03-05 2016-09-29 Ucb Biopharma Sprl Multimeric fc proteins
WO2015168643A2 (en) 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
SG11201609917PA (en) * 2014-05-29 2016-12-29 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
CN109963869A (zh) 2016-05-23 2019-07-02 动量制药公司 与经改造的Fc构建体相关的组合物和方法
JP7146771B2 (ja) * 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法

Also Published As

Publication number Publication date
CN118206639A (zh) 2024-06-18
IL263213B1 (en) 2024-01-01
US11155640B2 (en) 2021-10-26
SG11201810466PA (en) 2018-12-28
AU2017272111A1 (en) 2019-01-17
WO2017205436A1 (en) 2017-11-30
EP3484514B1 (en) 2023-12-06
US20240067757A1 (en) 2024-02-29
JP2022095685A (ja) 2022-06-28
US20190284305A1 (en) 2019-09-19
IL263213B2 (en) 2024-05-01
JP2019519528A (ja) 2019-07-11
KR20190021255A (ko) 2019-03-05
US20220049019A1 (en) 2022-02-17
EP3464376A4 (en) 2020-03-18
US11623964B2 (en) 2023-04-11
JP7045333B2 (ja) 2022-03-31
IL263213A (en) 2018-12-31
CN116063540A (zh) 2023-05-05
KR102462084B1 (ko) 2022-11-02
AU2017272109A1 (en) 2019-01-17
CA3025310A1 (en) 2017-11-30
US20210221917A1 (en) 2021-07-22
CN109789203B (zh) 2022-08-05
AU2017272111B2 (en) 2024-05-16
CN109789203A (zh) 2019-05-21
KR20220151025A (ko) 2022-11-11
KR20190026684A (ko) 2019-03-13
EP3484514A1 (en) 2019-05-22
WO2017205434A1 (en) 2017-11-30
EP3484514A4 (en) 2020-08-12
SG10202011624SA (en) 2021-01-28
DK3484514T3 (da) 2024-01-29
JP7295301B2 (ja) 2023-06-20
IL263211B1 (en) 2023-05-01
IL263211B2 (en) 2023-09-01
IL263211A (en) 2018-12-31
SG11201810465RA (en) 2018-12-28
ES2973251T3 (es) 2024-06-19
JP2019519527A (ja) 2019-07-11
PL3484514T3 (pl) 2024-04-29
IL309293A (en) 2024-02-01
KR102635635B1 (ko) 2024-02-14
KR102590061B1 (ko) 2023-10-18
EP3464376A1 (en) 2019-04-10
JP7045333B6 (ja) 2022-05-06
AU2017272109B2 (en) 2024-07-25
CN109963869A (zh) 2019-07-02
JP2022068176A (ja) 2022-05-09
BR112018074032A2 (pt) 2019-02-26
CA3025306A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
BR112018074056A2 (pt) composições e métodos relacionados a construtos de fc manipulados
BR112018008901A8 (pt) formulações subcutâneas de anticorpos anti-cd 38 e seus usos
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
DK3411404T3 (da) Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112017023943A2 (pt) anticorpos heterodimêricos que ligam cd3 e antígenos de tumor
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DK3504241T3 (da) Anti-cd3-antistofformuleringer
BR112017001796A2 (pt) composições de flagelina e seus usos
BR112017009297A2 (pt) anticorpos antifator de complemento c1q humanizados e usos dos mesmos
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
DK3475303T3 (da) Anti-cd19-antistofformuleringer
BR112018002382A2 (pt) novos anticorpos anti-gvpi humano e usos dos mesmos
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
BR112017015880A2 (pt) anticorpos, usos e métodos
PH12020550930A1 (en) Human igg fc domain variants with improved effector function
BR112021011124A2 (pt) Anelossomos e métodos de uso
BR112018009004A2 (pt) conjugados anti-cd3-folato e seus usos
UY36306A (es) Sintesis de ent-progesterona e intermediarios de la misma

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]